Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T16:37:56.133Z.
Calculation as of: 2026-10-06T16:37:56.133Z.
Quote observation: 2026-10-06T16:35:07.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 0fde8dae4c5ae63ee7b35c7e6e46bba2fdf5d6d5db310b32cf0eb41a7e17e840
PE RATIO
N/A
Market Cap
$997.66M
PE Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$984.60M
PE Ratio
71.25
TTM Avg
118.14
3Y Avg
119.36
5Y Avg
99.91
Market Cap
$1.03B
PE Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.04B
PE Ratio
N/A
TTM Avg
50.11
3Y Avg
34.45
5Y Avg
50.26
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Latigo Biotherapeutics Inc. (LTGO) | $1.00B | N/A | N/A | N/A | N/A |
| LB Pharmaceuticals Inc Common Stock (LBRX)vs › | $997.66M | N/A | N/A | N/A | N/A |
| PROCEPT BioRobotics Corporation (PRCT)vs › | $989.59M | N/A | N/A | N/A | N/A |
| MeiraGTx Holdings plc (MGTX)vs › | $986.75M | 15.01 | 18.35 | 18.35 | 18.35 |
| Pacira BioSciences, Inc. (PCRX)vs › | $984.60M | 71.25 | 118.14 | 119.36 | 99.91 |
| Aktis Oncology, Inc. (AKTS)vs › | $981.04M | N/A | N/A | N/A | N/A |
| Lumexa Imaging Holdings, Inc. Common Stock (LMRI)vs › | $1.03B | N/A | N/A | N/A | N/A |
| Immatics N.V. (IMTX)vs › | $1.04B | N/A | 31.31 | 24.04 | 24.04 |
| Integra LifeSciences Holdings Corporation (IART)vs › | $1.04B | N/A | 50.11 | 34.45 | 50.26 |
| Janux Therapeutics, Inc. (JANX)vs › | $1.04B | N/A | N/A | N/A | N/A |
Trailing P/E
N/A
Forward P/E
N/A
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
